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ABSTRACT While the inﬂammatory response to severe pneumonia is paramount in
limiting and resolving the infection, excessive inﬂammation can lead to deleterious
effects. We theorized that patients with severe community-acquired pneumonia
(CAP) who were treated with macrolides and aspirin would receive beneﬁt beyond
that of conventional antibiotic therapy. An observational study was conducted with
patients with severe CAP. All patients were admitted to 5 teaching hospitals (in Italy,
the United States, Japan, and China), and data were gathered from their electronic
medical records. Severe pneumonia was deﬁned according to Infectious Diseases So-
ciety of America/American Thoracic Society criteria. Patients were divided into 4
groups, i.e., (i) the aspirin-only group (ASG), (ii) the macrolide-only group (MG), (iii)
the aspirin plus macrolide group (ASMG), or (iv) the neither aspirin nor macrolide
group (NASMG). Survival rates for the 4 groups were evaluated after adjustment for
confounders and after weighting by propensity score. A total of 1,295 patients were
included in the analysis. There were 237 patients (18.3%) in the ASG, 294 (22.7%) in
the MG, 148 (11.4%) in the ASMG, and 616 (47.6%) in the NASMG. The mortality rate
at 30 days was 15.5% in the ASMG, compared to 28.2% in the NASMG, 23.8% in the
MG, and 21.1% in the ASG. After propensity score analysis, receipt of aspirin plus
macrolide (hazard ratio, 0.71 [95% conﬁdence interval, 0.58 to 0.88]; P 0.002) was
associated with a higher 30-day survival rate. This is a hypothesis-generating study
in which data suggest that the combination of aspirin plus a macrolide improves 30-
day survival rates for patients with severe CAP. Further randomized studies will need
to be undertaken to conﬁrm this phenomenon.
KEYWORDS aspirin, community-acquired pneumonia, macrolides, septic shock,
severe pneumonia
Community-acquired pneumonia (CAP) is the most common type of infectionleading to hospitalization in intensive care units (ICUs) and the most common
cause of death associated with infectious diseases (1–3). Despite the advances in
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antimicrobial therapy and the improvements in intensive care medicine, diagnosis of
severe pneumonia is associated with mortality rates as high as 50% (4, 5).
The high mortality rates observed for patients with severe pneumonia are related to
the development of sepsis and/or septic shock; the disease progression is associated
with an overwhelming inﬂammatory reaction, and it has been suggested that the use
of agents that interfere with the pathogenesis of sepsis by modulating inﬂammation
and coagulation, including agents with anti-inﬂammatory properties, such as macro-
lides, steroids, aspirin, statins, or others (6, 7), may hamper that process. Different
meta-analyses showed that the addition of a macrolide antibiotic to a -lactam reduced
mortality rates for patients with severe CAP (8, 9). A retrospective study also suggested
that macrolide use was associated with reduced mortality rates for septic patients with
pneumonia due to macrolide-resistant pathogens (10); more recently, the use of a
modiﬁed macrolide lacking antibiotic activity but retaining anti-inﬂammatory proper-
ties dramatically improved the survival rates for levoﬂoxacin-treated mice with Pseu-
domonas aeruginosa respiratory infections (11). Moreover, experimental studies dem-
onstrated that lungs of infected mice are massively inﬁltrated by aggregates of
activated platelets and activation of protease-activated receptor 4, a platelet receptor
for thrombin, exacerbates inﬂuenza-induced acute lung injury and promotes death (12).
Low-dose aspirin, which inhibits platelet aggregation through irreversible acetylation of
cyclooxygenase 1 (COX1), has been associated with improved survival rates for patients
with CAP (13). Since limited clinical data exist regarding the prognostic role of macro-
lide and aspirin therapy for patients with severe CAP, we aimed to evaluate the possible
role of the combination of aspirin plus a macrolide in a large multinational cohort, to
generate a hypothesis to support eventual randomized trials.
RESULTS
During the study period, a total of 1,295 patients with severe CAP were included.
Overall, the 30-day mortality rate was 24.4%. Baseline characteristics of the population
are reported in the supplemental material (see Table S1 at https://www.alariconetwork
.com/novita-scientiﬁche). The distribution of patients in the 4 study groups was as
follows: 237 patients (18.3%) received only aspirin, 294 patients (22.7%) received only
a macrolide, 148 patients (11.4%) received a combination of aspirin plus a macrolide,
and 616 patients (47.6%) received neither aspirin nor a macrolide (Fig. 1). For all
patients in the aspirin groups, prehospital use of aspirin before the pneumonia event
was reported.
Demographic, anamnestic, and clinical characteristics of the patients with severe
pneumonia in the 4 study groups are reported in Table 1. All patients belonged to the
higher-risk classes, based on pneumonia severity index (PSI) and CURB-65 scores;
patients in the aspirin-only group (ASG) showed a higher frequency of 2 comorbidi-
ties (63.3%), while a multidrug-resistant (MDR) etiology (22.2%) was more frequently
reported in the neither aspirin nor macrolide group (NASMG). Table S2 in the supple-
mental material at https://www.alariconetwork.com/novita-scientiﬁche reports patho-
gens isolated from 373 patients with culture-positive severe pneumonia.
Radiological features, laboratory ﬁndings, and outcomes for patients with severe
pneumonia in the 4 study groups are presented in Table 2. A higher incidence of
cardiovascular events during hospitalization was observed in the ASG (23.2%), while the
use of inotropic agents (37.1%) and septic shock (39.2%) were more frequently ob-
served in the aspirin plus macrolide group (ASMG). Patients in the NASMG had the
higher 30-day mortality rate (28.2%), followed by the macrolide-only group (MG)
(23.8%), the ASG (21.1%), and the ASMG (15.5%). Inclusion in the ASMG was associated
with improved outcomes in comparison to the NASMG (P  0.001) and the MG (P 
0.04) but not in comparison to the ASG (P 0.12).
Cox regression analysis after propensity score weighting showed that the use of
aspirin plus a macrolide in combination was associated with an increased 30-day
survival rate (hazard ratio [HR], 0.71 [95% conﬁdence interval [CI], 0.58 to 0.88];
P 0.002). The HRs for 30-day deaths among the 4 study groups are reported in Fig. 2.
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The use of aspirin plus a macrolide in combination showed a protective effect in
comparison to ﬁndings for the NASMG (HR, 1.39 [95% CI, 1.12 to 1.71]; P 0.002) and
the MG (HR, 1.54 [95% CI, 1.24 to 1.9]; P 0.001), while there was no signiﬁcant effect
in comparison to ﬁndings for the ASG (HR, 1.185 [95% CI, 0.95 to 1.47]; P 0.122).
Kaplan-Meier curves for 30-day survival rates for the 4 study groups are reported in Fig.
3. Propensity score-weighted survival curves are reported in Fig. S1 at https://www
.alariconetwork.com/novita-scientiﬁche. The balancing properties of our model are
reported in Table S3 at https://www.alariconetwork.com/novita-scientiﬁche.
DISCUSSION
Our study suggests that, for patients with severe CAP, the combination of low-dose
aspirin (100 mg/day) plus a macrolide is associated with improved 30-day survival
rates. To our knowledge, this is the ﬁrst study demonstrating, in a large cohort of
patients, the role of these drugs in combination for patients hospitalized in the
emergency department with severe pneumonia.
Antibiotic therapy alone may not be sufﬁcient to reduce mortality rates for septic
patients with pneumonia. After the initial administration of effective antibiotic therapy,
most bacteria are killed within the ﬁrst 24 h of therapy (14) but, despite a marked
reduction or clearance of the bacterial inoculum, the progression to sepsis or septic
shock may eventually ensue until death, and antibiotic therapy alone may not be
sufﬁcient to halt this process. Macrolides and aspirin are drugs with well-recognized
anti-inﬂammatory effects. Macrolides have multiple immunomodulatory effects, and
long-term use of macrolides has been associated with increased survival rates in various
lung diseases characterized by chronic airway inﬂammation, such as cystic ﬁbrosis and
asthma (15). A recent study using a mouse model showed that, in lethal pneumococcal
pneumonia, macrolides can restore immune functions (16). Moreover, clinical studies
conducted with patients admitted to the ICU with severe CAP identiﬁed macrolide use
as a factor associated with lower ICU mortality rates (17). Similarly, the administration
of clarithromycin has been associated with restoration of the balance between proin-
FIG 1 Flow chart for the study.
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ﬂammatory and anti-inﬂammatory mediators in patients with ventilator-associated
pneumonia (VAP) (18).
Aspirin has several anti-inﬂammatory activities (19). It is able to inhibit platelet
activation in sepsis, stimulating the formation of anti-inﬂammatory lipoxin A4 (20), with
a protective effect against acute lung injury. Chen and coworkers found that critically
ill patients taking aspirin had a signiﬁcantly lower prevalence of adult respiratory
distress syndrome (ARDS) (27% versus 34%; P 0.034) (21). Chronic aspirin therapy has
been also associated with improved survival rates for both patients with CAP (13) and
those with sepsis (22).
The novelty of our study is that we found a synergistic effect of aspirin and
macrolides. Our study suggests that aspirin and macrolides have different and com-
plementary effects in patients with severe pneumonia. The prehospital use of aspirin
combined with the initial in-hospital use of a macrolide may interfere with the
overwhelming inﬂammatory response. Furthermore, as suggested by previous studies
(1, 8, 23, 24), the antiplatelet activity of aspirin may reduce the occurrence of acute
cardiovascular events secondary to pneumonia, with a beneﬁcial effect on mortality
rates. As a matter of fact, the mortality rate observed in the ASMG was lower than that
observed in the other groups, despite those patients having a higher frequency of
previous cardiovascular diseases; as shown in Fig. 3, differences in survival rates among
the 4 study groups were substantially observed after the ﬁrst 10 days of treatment. This
ﬁnding may be due to the role of aspirin in improving survival rates for patients at
highest risk of cardiovascular complications due to baseline chronic heart disease
(25, 26).
However, it is important to consider that therapy with macrolides and aspirin also
has some disadvantages. For example, the greater bacteremia observed in the aspirin
group may result from blocking of the beneﬁt of platelets on extracellular traps and
TABLE 1 Demographic and clinical features of patients with severe pneumonia in the 4 study groups
Variablea ASMG (n  148) ASG (n  237) MG (n  294) NASMG (n  616) Pb
Baseline characteristics
Age (median [IQR]) (yr) 79 (69–82) 79 (68–81) 75 (69–82) 76 (68–82) 0.001
Male (no. [%]) 94 (63.5) 156 (65.8) 173 (58.8) 386 (62.6) 0.41
2 comorbidities (no. [%]) 82 (55.4) 150 (63.3) 133 (45.2) 277 (44.9) 0.001
Charlson Comorbidity Index (median [IQR]) 3 (1–5) 3 (1–5) 3 (1–5) 3 (1–5) 0.51
Chronic heart disease (no. [%]) 54 (36.4) 93 (39.2) 56 (19) 136 (22.1) 0.001
Chronic liver disease (no. [%]) 3 (2) 11 (4.6) 11 (3.7) 38 (6.1) 0.13
Diabetes mellitus (no. [%]) 54 (36.4) 82 (34.6) 52 (17.7) 132 (21.4) 0.001
Neoplasm (no. [%]) 24 (16.2) 31 (13.1) 59 (20) 159 (25.8) 0.001
Chronic renal failure (no. [%]) 37 (25) 50 (21.1) 34 (11.5) 86 (13.9) 0.001
Hemodialysis (no. [%]) 5 (3.3) 15 (6.3) 5 (1.7) 15 (2.4) 0.007
COPD (no. [%]) 32 (21.6) 62 (26.1) 72 (24.5) 104 (16.8) 0.006
PPI/H2 blocker (no. [%]) 76 (51.3) 141 (59.5) 139 (47.3) 283 (45.9) 0.001
Previous antibiotic therapy (30 days) (no. [%]) 22 (14.8) 43 (18.1) 75 (25.5) 169 (27.4) 0.004
Immunosuppressive therapy (no. [%]) 25 (16.9) 50 (21.1) 74 (25.1) 123 (19.9) 0.21
LTCF (no. [%]) 6 (4) 21 (8.8) 26 (8.8) 66 (10.7) 0.29
Clinical features and disease severity
Delirium at pneumonia onset (no. [%]) 34 (23) 78 (32.9) 75 (25.5) 247 (40.1) 0.001
Tachypnea (30 breaths/min) (no. [%]) 42 (28.3) 94 (39.6) 116 (39.4) 222 (36) 0.88
Fever (no. [%]) 88 (59.4) 97 (40.9) 133 (45.2) 292 (47.4) 0.004
CVC (no. [%]) 21 (14.2) 61 (25.7) 62 (21.1) 89 (14.4) 0.001
Bacteremia (no. [%]) 31 (20.9) 81 (34.1) 62 (21.1) 151 (24.5) 0.006
Glasgow Coma Scale score (median [IQR]) 11 (3–13) 14 (5–15) 14 (4–15) 13 (3–15) 0.001
PSI class IV (no. [%]) 44 (29.7) 60 (25.3) 76 (25.8) 182 (29.5) 0.45
PSI class V (no. [%]) 87 (58.8) 130 (54.8) 152 (51.7) 322 (52.2) 0.26
CURB-65 class II (no. [%]) 51 (34.4) 53 (22.3) 60 (20.4) 170 (27.6) 0.008
CURB-65 class III (no. [%]) 74 (50) 128 (54) 146 (49.6) 326 (52.9) 0.25
Septic shock (no. [%]) 58 (39.2) 61 (25.7) 61 (20.7) 182 (29.5) 0.001
aIQR, interquartile range; PSI, pneumonia severity index; LTCF, long-term-care facility; COPD, chronic obstructive pulmonary disease; PPI, proton pump inhibitor; CVC,
central venous catheter; ASMG, aspirin plus macrolide group; ASG, aspirin-only group; MG, macrolide-only group; NASMG, no aspirin or macrolide group.
bDescriptive P values for the nonparametric ANOVA/chi-square hypothesis that 1 group differs from the others.
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other attempts to prevent bacteria from gaining access to the vascular space. This
effect could be overcome in a randomized clinical trial by starting aspirin therapy after
admission for CAP. Finally, clinicians should carefully weigh the potential cardiovascular
adverse effects of macrolides, especially for patients with a high risk of arrhythmias (27).
Our study has some strengths and several limitations. The observational design of
the study is an intrinsic limitation, because lack of randomization precludes deﬁnitive
analysis of the beneﬁt of aspirin plus macrolides, and the sample size planned in the
protocol was not reached for the ASMG. We attempted to reduce the potential bias due
to confounding variables that could be found in an estimate of the treatment effect
obtained by simply comparing outcomes by using the propensity score matching
technique. Moreover, the population analyzed was very old (the median age was
TABLE 2 Radiological features, laboratory ﬁndings, and outcomes for patients with severe pneumonia in the 4 study groups
Variablea ASMG (n  148) ASG (n  237) MG (n  294) NASMG (n  616) Pb
Radiological and laboratory ﬁndings
Pleural effusion (no. [%]) 56 (37.8) 112 (47.2) 121 (41.1) 244 (39.6) 0.06
Bilateral pneumonia (no. [%]) 61 (41.2) 102 (43) 176 (59.8) 323 (52.4) 0.001
Leukocytosis (leukocyte count of 10,000
leukocytes/l) (no. [%])
67 (45.3) 143 (60.3) 177 (60.2) 371 (60.2) 0.10
Leukopenia (leukocyte count of 4,000
leukocytes/l) (no. [%])
20 (13.5) 48 (20.2) 102 (34.7) 236 (38.3) 0.001
Uremia (BUN level of 20 mg/dl) (no. [%]) 61 (41.2) 126 (53.1) 171 (58.1) 303 (49.2) 0.77
Platelet count of 100,000 mm3 (no. [%]) 11 (7.4) 49 (20.6) 65 (22.1) 99 (16.1) 0.07
PaO2/FiO2 ratio of 250 (no. [%]) 74 (50) 127 (53.6) 174 (59.2) 356 (57.8) 0.15
MDR etiology (no. [%]) 17 (11.4) 38 (16) 32 (10.9) 137 (22.2) 0.001
Therapies
Use of inotropic agents (no. [%]) 55 (37.1) 56 (23.6) 57 (19.4) 178 (28.9) 0.001
CRRT (no. [%]) 10 (6.7) 21 (8.8) 24 (8.1) 50 (8.1) 0.82
ARDS (no. [%]) 17 (11.4) 18 (7.6) 28 (9.5) 84 (13.6) 0.08
NIV use (no. [%]) 32 (21.6) 25 (10.5) 48 (16.3) 86 (13.9) 0.006
Mechanical ventilation (no. [%]) 20 (13.5) 55 (23.2) 50 (17) 96 (15.6) 0.03
Outcomes
Cardiovascular events during hospitalization (no. [%]) 37 (25) 55 (23.2) 45 (15.3) 104 (16.8) 0.007
Length of hospitalization (median [IQR]) (days) 11 (1–26) 15 (1–26) 12 (1–25) 15 (3–28) 0.001
Length of therapy (median [IQR]) (days) 11 (1–13) 10 (1–15) 10 (3–13) 11 (4–14) 0.026
Admission to ICU (no. [%]) 32 (21.6) 86 (36.3) 101 (34.3) 211 (34.2) 0.045
30-day death (no. [%]) 23 (15.5) 50 (21.1) 70 (23.8) 174 (28.2) 0.005
aIQR, interquartile range; CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome; NIV, noninvasive ventilation; ASMG, aspirin plus
macrolide group; ASG, aspirin-only group; MG, macrolide-only group; NASMG, no aspirin or macrolide group.
bDescriptive P values for the nonparametric ANOVA/chi-square hypothesis that 1 group differs from the others.
FIG 2 HRs for 30-day death among the 4 study groups after propensity score weighting. ASMG, aspirin
plus macrolide group; ASG, aspirin-only group; MG, macrolide-only group; NASMG, no aspirin or
macrolide group.
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77 years), and these data should not be extrapolated to all patients with community-
onset pneumonia. As shown in Table 1, few patients who had septic shock or were
treated with inotropic agents were admitted to ICUs, especially in the ASMG. The
potential explanation for this ﬁnding could be that patients with septic shock died in
the emergency department, before transfer to other wards. Finally, considering the
possible role of aspirin in reducing cardiovascular events, a subanalysis of differences in
aspirin dosages and effects on survival rates was not performed. Further studies,
preferably randomized clinical trials, are needed to evaluate this potential mechanism.
The strength of the study is its international multicenter design and the analysis of
severe pneumonia in real settings, which suggests that aspirin in combination with
macrolides may have a positive impact on mortality rates independent of other
confounding factors. Of importance, users of aspirin plus macrolides and nonusers of
aspirin plus macrolides were well balanced in terms of demographic and clinical
characteristics and had no differences in concomitant diseases, which could bias the
results.
In conclusion, our study provides clinical evidence that the combination of aspirin
plus a macrolide could improve survival rates for patients with severe CAP; the optimal
management of severe CAP may consist of a multifaceted therapeutic approach with
antimicrobial, anti-inﬂammatory, and antiplatelet agents. Considering the observational
methodology of the study, randomized clinical trials are warranted to support this
ﬁnding.
MATERIALS AND METHODS
Study design and patient selection. This observational study was conducted between 2011 and
2015 with patients enrolled in the following university hospitals: (i) Policlinico Umberto I, Sapienza
University of Rome (Rome, Italy); (ii) Division of Pulmonary and Critical Care Medicine, Washington
University School of Medicine (St. Louis, MO, USA); (iii) Nagoya University Graduate School of Medicine
(Nagoya, Japan); (iv) Zhejiang University School of Medicine (Hangzhou, China); and (v) Internal and
Emergency Medicine Unit, Careggi General and University Hospital (Florence, Italy). The availability of
FIG 3 Kaplan-Meier curves of 30-day survival rates after propensity score analysis. ASMG, aspirin plus
macrolide group; ASG, aspirin-only group; MG, macrolide-only group; NASMG, no aspirin or macrolide
group.
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standard methods for diagnosis and the possibility to apply the same study design and to establish
identical outcomes provided the rationale to pool patients’ data. Patients who fulﬁlled the following
criteria were enrolled in the study: (i) age of 18 years; (ii) clinical presentation of an acute illness with
2 of the following signs or symptoms suggesting pneumonia: rales, rhonchi, bronchial breath sounds,
fever (38.0˚C), tachycardia, chills, dyspnea, coughing (with or without sputum), and/or chest pain; (iii)
presence of new consolidation(s) on chest X rays; and (iv) criteria for severe pneumonia (5). This analysis
was reported according to the STROBE recommendations (28).
Only patients who were treated with aspirin before admission were included in the study, while
patients who received aspirin during hospitalization were not recruited. Prehospital use of aspirin was
deﬁned according to the patients’ pharmacological history. Patients who had an anamnestic or new
intolerance/allergy to a macrolide or aspirin, had a rapidly progressive neoplasm, or had received a solid
organ or hematopoietic stem cell transplant were excluded from the ﬁnal analysis. Patients who had
received macrolides prior to hospitalization were also excluded. Pneumonia was considered CAP if it was
diagnosed upon hospitalization and the patient had not been discharged from an acute care facility
within 14 days preceding the clinical presentation (29). The present study was conducted according to
the principles stated in the Declaration of Helsinki. The local ethics committees of all participating
hospitals approved the study.
Baseline assessment and deﬁnitions. Data on demographic characteristics, comorbidities, and
antibiotic and concomitant therapy were collected. Baseline comorbidities were deﬁned as described
previously (30). Baseline treatments were deﬁned according to the patients’ pharmacological history.
Stratiﬁcation of the severity of pneumonia at presentation was performed using PSI and CURB-65 scores
(31). Intrahospital cardiovascular events, as deﬁned previously (32), were recorded.
Diagnosis of severe pneumonia was based on the Infectious Diseases Society of America/American
Thoracic Society consensus guidelines (5), i.e., 1 major criterion (invasive mechanical ventilation or septic
shock with the need for vasopressors) or 3 minor criteria (respiratory rate of 30 breaths/min, partial
pressure of arterial oxygen [PaO2]/fraction of inspired oxygen [FiO2] ratio of 250, multilobar inﬁltrates,
confusion/disorientation, uremia [blood urea nitrogen [BUN] level of 20 mg/dl], leukopenia [white
blood cell [WBC] count of4,000 cells/mm3], thrombocytopenia [platelet count of100,000 cells/mm3],
hypothermia [core temperature of 36°C], or hypotension requiring aggressive ﬂuid resuscitation) (5).
Sepsis and septic shock were deﬁned according to the new deﬁnitions of 2016 (38). For patients who
underwent an etiological diagnosis, microbiological examinations performed on blood and respiratory
specimens during the ﬁrst 24 h after admission, according to standards of practice, were evaluated for
assessment of microbial etiology. The etiology was considered deﬁnite if 1 of the following criteria was
met (17): positive blood culture in the absence of an apparent extrapulmonary focus; positive bacterial
culture of pleural ﬂuid; positive urinary antigen for Legionella pneumophila; positive urinary antigen for
Streptococcus pneumoniae; bacterial yield in cultures of valid sputum (25 polymorphonuclear cells and
10 epithelial cells per high-power ﬁeld) of106 CFU/ml, of tracheobronchial aspirates of105 CFU/ml,
of bronchoalveolar lavage ﬂuid of 104 CFU/ml, or of protected specimen brush cultures of 103
CFU/ml; or occurrence of seroconversion (a 4-fold increase in IgG titers for Chlamydophila pneumoniae
[1:512] or an increase in IgM titers for C. pneumoniae [1:32] or Mycoplasma pneumoniae [any titer]).
Diagnostic methods were similar for all study centers. Patients were considered to have MDR pathogens
if one of the following was isolated: methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomo-
nas maltophilia, or extended-spectrum -lactamase (ESBL)-producing or carbapenem-resistant Entero-
bacteriaceae. For the remaining cases, MDR was deﬁned as isolation of a bacterial strain that was
nonsusceptible to 1 agent in 3 antimicrobial categories (33).
Study groups and endpoints. Four study groups were identiﬁed, i.e., (i) patients receiving aspirin
plus macrolides (ASMG), (ii) patients receiving aspirin alone (ASG), (iii) patients receiving a macrolide
alone (MG), and (iv) patients receiving neither aspirin or macrolides (NASMG) We considered patients
taking aspirin if their daily intake was 100 mg. Compliance with therapy was assessed by collection of
medical history at the time of hospitalization. All patients were considered receiving macrolide treatment
if they received 48 h of therapy with 500 mg of clarithromycin every 12 h or 500 mg of azithromycin
every 24 h. The primary endpoint was the evaluation of 30-day survival rates for patients with severe
pneumonia treated with aspirin plus macrolides, compared to the other groups.
Sample size. The primary endpoint concerned the supremacy of the combination therapy (ASMG),
with respect to the other groups, in increasing the 30-day survival rate. We tested the union null
hypothesis that the combination therapy was equivalent to each of the other 3 groups. Consequently,
a union-intersection test was built, and its P value was the one corresponding to the largest of the 3 P
values computed. Assuming a survival rate of 85% for the ASMG, a survival rate of 75% for the ASG, and
lower survival rates for the other 2 groups, a sample size of 247 patients per group was calculated to
guarantee a power of 80% to detect a signiﬁcant difference, with a signiﬁcance level of 5%.
Statistical analysis. Data were collected through an electronic database. The results obtained were
analyzed using commercially available statistical software packages (SPSS v20.0 [SPSS Inc., Chicago, IL]
and R v3.3.3 [R Development Core Team]).
To detect signiﬁcant differences between groups, we used the chi-square test or the Fisher exact test
for categorical variables and the 2-tailed t test or the Mann-Whitney test for continuous variables, as
appropriate. Comparisons among 3 groups were performed with univariate analysis of variance
(ANOVA) or the Kruskal-Wallis test, as appropriate. Post hoc tests were adjusted for multiplicity through
Bonferroni correction. We report adjusted signiﬁcance levels, which can be interpreted as usual P values.
Survival curves for time-to-event variables were constructed with the use of Kaplan–Meier estimates
based on all available data and were compared with the use of the log-rank test. In a multivariate analysis
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of survival times, the Cox regression model was used to determine the effects of different variables on
overall survival rates. Wald CIs and tests for odds ratios were computed based on the estimated standard
errors.
Finally, to correct for possible bias arising from the observational nature of the experiment, we
weighted all relevant effect estimates and P values by propensity score analysis (34), using relevant
prehospitalization variables and factors measured at the time of hospital admission. We determined the
candidate variables a priori, referring to reported risk factors for death in previous studies (3, 5, 10, 18,
35, 36, 37). The variables included age, sex, CURB-65 class III, presence of 2 comorbidities, cardiovas-
cular disease, liver disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD), renal
disease, neoplasm, previous hospitalization, pleural effusion, delirium, PaO2/FiO2 ratio of 250, ARDS,
bacteremia, leukopenia, MDR etiology, septic shock, and ICU admission (a full description is provided in
Table S3 at https://www.alariconetwork.com/novita-scientiﬁche). The propensity score for the 4 treat-
ment levels was estimated using boosted logistic regression, by minimizing the maximal standardized
difference between each pair of treatment levels for each pretreatment variable.
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